Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Selinexor in Recurrent Gliomas
2013-003668-30Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in glioblastoma (GBM), anaplastic astrocytoma (AA) and brain cancer, sponsored by Karyopharm Therapeutics Inc. Primary endpoint: 6-month progression-free survival rate. Started Nov 2013; status: terminated.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)brain cancer
Beyond the preview
Go deeper on 2013-003668-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003668-30.